There were 42 studies in total: 29 RCTs and 13 case series.
The effects of both the combined continuous (decline of 14.4 mg/dL) and sequential (decline of 14.9 mg/dL) regimens produced a statistically significant treatment-associated decline in total cholesterol. The two regimens did not differ significantly in their ability to lower total cholesterol. A significant treatment-associated decrease in low-density lipoprotein cholesterol with combined continuous therapy was found (17 mg/dL) and with the sequential regimen (18.4 mg/dL). Again, no significant differences between the two regimens were found. High-density lipoprotein levels increased significantly with combined continuous HRT (1.9 mg/dL) and with the sequential regimen (3.1 mg/dL). Again, no significant differences between the two regimens were found.
Improvements were noted in vasomotor symptoms (the 13 studies examining this all found improvements post-intervention).
Uterine bleeding was found to be a common problem in the first 6 months of treatment, although there was wide variation in frequency between studies (0 - 93%). Thereafter rates of amenorrhea of 75% or greater were reported.
Most patients undergoing endometrial biopsy showed atrophic endometrium (90-100%).
Compliance with HRT was high (around 80%, but with quite a wide spread 35% - 100%).
9 studies looked at bone density and all revealed either no change or an increase in bone density over time.